Language:
Search:
Login
Press Releases

West Announces the Commercial Launch of the B.safe(TM) Syringe Safety System Technology Platform

LIONVILLE, Pa., Sept. 11, 2012 /PRNewswire via COMTEX/ --West (NYSE: WST), a leading global developer and manufacturer of components and systems for injectable drug delivery, announces the commercial introduction of its B.safe(TM) syringe safety system. West acquired the IP and rights to this system in 2011 and has completed the product development and first phase of commercial scale-up at its safety systems manufacturing center in France. Significant scale-up to high-volume manufacturing will be achieved in the first half of 2013, in order to meet market demands.

(Logo: http://photos.prnewswire.com/prnh/20120904/NE65950LOGO )

The system is designed to help protect against needlestick injury when using a prefilled syringe and will complement West's portfolio of prefilled syringe offerings and technologies. West's portfolio includes the NovaGuard(TM) passive needle system for Luer Lock syringes and the eris(TM) system, of which more than 1 billion units have been manufactured and used in the market with exceptional performance in the hands of healthcare workers and patients.

"We are delighted to reach this significant milestone and be in a position to offer our customers a globally available safety system, leveraging our established expertise around prefilled syringes and needle safety," said Glenn Thorpe, Vice President, Strategic Market Development, Syringe Systems. "With the completion of the steps necessary to offer this system commercially, we are in position to meet growing market demand in this area, and are pleased to have already signed our first commercial agreement and commenced shipments."

Click here for more information on the B.safe syringe safety system technology.

About West

West's innovative system, device and component solutions help improve the safety and administration of injectable drugs. West's proprietary materials science, formulation research and manufacturing technologies advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics and vaccines. Sales in 2011 totaled US$1.2 billion. West supports its customers from sales, manufacturing, customer support and research and development locations in North and South America, Europe, Asia and Australia. Global headquarters are in Lionville, Pa., USA. Visit West online at http://www.westpharma.com. Follow West on Twitter: http://www.twitter.com/WestPharma.

B.safe(TM) is a registered trademark of Tech Group Europe, Ltd., a subsidiary of West Pharmaceutical Services, Inc.

NovaGuard(TM) is a trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions

eris(TM) is a trademark of Tech Group Europe, Ltd., a subsidiary of West Pharmaceutical Services, Inc.

Media Contact:
Kristin Villiotte
Schwartz MSL
(781) 684-0770
westpharma@schwartzmsl.com

Investor Contact:
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345
Michael.Anderson@westpharma.com

SOURCE West

SITEMAP | Partnerships | Legal Notice | Visit WestPFSSolutions.com Copyright 2012 West Pharmaceutical Services, Inc.
Investors